Labcorp Perspectives: Oncology | How can HRD testing help patients with ovarian cancer?

Presented by:

Dr. Rebecca Previs, MD, Director of Medical Affairs at Labcorp

Dr. Alison Roos, PhD, Associate Director of Medical Affairs at Illumina

Dr. Alison Roos, an expert in personalized cancer care, discusses homologous recombination deficiency (HRD) testing, an important diagnostic tool for ovarian cancer treatment. About 1 in 2 patients with advanced ovarian cancer patients have an HRD-positive tumor. In the absence of a BRCA1/2 mutation, homologous recombination status may provide information on the magnitude of benefit of PARP inhibitor therapy. In this episode of Labcorp Perspectives: Oncology, Dr. Roos shares that while most patients are tested for BRCA1 and BRCA2 mutations, data show that less than half receive HRD testing. This gap highlights the need for wider use of HRD testing to improve treatment decisions for patients with ovarian cancer.